MDXG vs. ATRC, AORT, FNA, KIDS, SILK, ATRI, TMCI, SIBN, EMBC, and IRMD
Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include AtriCure (ATRC), Artivion (AORT), Paragon 28 (FNA), OrthoPediatrics (KIDS), Silk Road Medical (SILK), Atrion (ATRI), Treace Medical Concepts (TMCI), SI-BONE (SIBN), Embecta (EMBC), and Iradimed (IRMD). These companies are all part of the "surgical & medical instruments" industry.
AtriCure (NASDAQ:ATRC) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.
AtriCure received 513 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 77.27% of users gave MiMedx Group an outperform vote while only 68.98% of users gave AtriCure an outperform vote.
MiMedx Group has a net margin of 18.63% compared to MiMedx Group's net margin of -8.98%. AtriCure's return on equity of 39.42% beat MiMedx Group's return on equity.
MiMedx Group has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
99.1% of AtriCure shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 3.2% of AtriCure shares are held by insiders. Comparatively, 1.3% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
AtriCure presently has a consensus price target of $49.78, suggesting a potential upside of 115.12%. MiMedx Group has a consensus price target of $12.25, suggesting a potential upside of 57.05%. Given MiMedx Group's higher possible upside, equities analysts plainly believe AtriCure is more favorable than MiMedx Group.
In the previous week, AtriCure had 4 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for AtriCure and 2 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.47 beat AtriCure's score of 0.00 indicating that AtriCure is being referred to more favorably in the media.
AtriCure has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.
Summary
MiMedx Group beats AtriCure on 9 of the 17 factors compared between the two stocks.
Get MiMedx Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiMedx Group Competitors List
Related Companies and Tools
